PET/CT and cross sectional imaging of gynecologic malignancy

Cancer Imaging

Volumn 7, Issue SPEC. ISS. A, 2007, Pages

  Iyer, Revathy B ^a,b   Balachandran, Aparna ^a   Devine, Catherine E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Cervical cancer; Endometrial cancer; Imaging; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; ORAL CONTRACEPTIVE AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; ENDOMETRIUM CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HUMAN; INTERMETHOD COMPARISON; LAPAROTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHANGIOGRAPHY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; OVARY CANCER; PATHOLOGICAL ANATOMY; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; UTERUS SURGERY; FEMALE GENITAL TRACT TUMOR; METASTASIS; PATHOLOGY; RADIOGRAPHY; REVIEW; SCINTISCANNING;

CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35848966994     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.9015     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Hricak H, Lacey CG, Sandles LG, et al. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology 1988; 166: 623-31.
3. Subak LL, Hricak H, Powell CB, et al. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995; 86: 46-50.
4. Matsukuma K, Tsukamoto N, Matsuyama T, Ono M. Nakano H. Pre-operative -CT study of lymph nodeg in cervical cancer: its correlation with histological findings. Gyncecol Oncol 1989; 33: 168-71.
5. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastatis with MR imaging. Radiology 1994; 190: 807-11.
6. Yang WT, Lam WM, Yu MY, Cheung TH, Metrewelli C. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 2000; 175: 759-66.
7. Scheidler J, Hricak H, Yu KK., Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer: a meta-analysls. JAMA 1997; 278: 1096-101.
8. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999; 40: 1125-31.
9. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19: 3745-9.
10. Sironi S, Buda A, Picchio M. et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection, with integrated PET/CT. Radiology 2006; 238: 272-9.
11. Singh AK; Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 489-93.
12. Morrow C, Cutin C, Paul M. Synopsis of gynecologic oncology. New York: Churchill Livingston; 1998.
13. Koonings PP, Cimpbell & Mishett Jr DR, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10 year review. Obstet Gynecol 1989; 74: 921-6.
14. Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. Radiographics 2000; 20: 1445-70.
15. Sassone AM, Timor-Tritsch IE, Artner, A, et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict malignancy. Obstet Gynecol 1991; 78: 70-6.
16. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994; 170: 81-5.
17. Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997; 25: 217-25.
18. Ferrazzi E, Zanetta G, Dordoni D, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997; 10: 192-7.
19. Hamper UM, Sheth S, Abbas FM, et al. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol 1993; 160: 1225-8.
20. Stein SM, Laifer-Narin S, Johnson ME, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color, Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995; 164: 381-6.
21. Brown DL, Frates MC, Laing FC, et al. Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 1994; 190: 333-6.
22. Carter J, Saltzman A, Hartenbach E, et al. Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow Doppler. Obstet Gynecol 1994; 83: 125-30.
23. Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994; 191: 63-7.
24. Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis - report of the Radiology Diagnostic Oncology Group. Radiology 1999; 212: 19-27.
25. Siegelman ES, Outwater EK. Tissue characterization in the female pelvis. Radiology 1999; 212: 5-18.
26. 18F] FDG). Gynecol Ortool 1993; 51: 197-204.
27. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol Clin North Am 2004; 42: 1155-67 (ix; review).
28. Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004; 28: 505-16.
29. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77: 454-9.
30. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223: 780-8.
31. 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging 2005; 32: 757-63.
32. Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532-40.
33. Yoshida Y, Kurokawa T, Kawahara K, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004; 182: 227-33.
34. Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Mod 1999; 44: 775-8.
35. Pannu HK, Bristow RE, Moritz FJ, Fishman EK. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiogiraphics 2003; 23: 687-701 (review).
36. Nakomoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176: 1449-54.
37. Picchio M, Sironi S, Messa C, et al. Advanced ovarian carcinoma: usefulness of [(18)F] FDG PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2003; 47: 77-84.
38. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519-28.
39. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.
40. Yen TC, Lai CH. Positron emission tomography in gynecologic cancer. Semin Nucl Med 2006; 36: 93-104.
41. Jobo T, Sito R, Arai T, Tamura T, Watanabe J, Kuramoto H. Lymph node pathway in the spread of endometrial carcinoma. Eur J Gynaecol Oncol 2005; 26: 167-9.
42. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212: 711-8.
43. Frei KA, Kinkel K. Staging endometrial cancer: role of magnetic resonance imaging. J Magn Reson Imaging 2001; 13: 850-5.
44. Frei KA, Kinkel K, Bonel HM, Lu Y, Zaloudek C, Hricak H. Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis. Radiology 2000; 216: 444-9.
45. 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004; 45: 266-71.
46. 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol 2004; 94: 680-4.
47. Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95: 546-51.
48. Nakahara T, Fujii H, Ide M, et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med 2001; 26: 82-3.
49. Lentz SS. Endometrial carcinoma diagnosed by positron emission tomography: a case report. Gynecol Oncol 2002; 86: 223-4.
50. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994; 170: 5 Pt 21499-507.
51. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG PET in the follow up of post-operative patients with endometrial cancer Ann Nucl Med 2003; 17: 197-203.
52. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J, et al. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002; 29: 1132-9.